- Investopedia•1 hour ago
Lilly trimmed its full-year GAAP EPS guidance, dragging shares lower today.
- Motley Fool•6 hours ago
Bristol-Myers Squibb might have fast-growing cancer drug Opdivo, but here's why Pfizer is the better dividend stock.
- PR Newswire•6 hours ago
Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease
CAMBRIDGE, Mass., April 25, 2017 /PRNewswire/ -- Aquinnah Pharmaceuticals, a privately held biotechnology company focused on RNA binding proteins for neurodegenerative disease, announced today that two additional pharmaceutical companies, Pfizer Inc. (PFE) and AbbVie Inc. (ABBV), have invested in Aquinnah's work to treat ALS (Amyotrophic Lateral Sclerosis), Alzheimer's disease and other neurodegenerative diseases. This $10 million adds to an earlier $5 million investment made by Takeda Pharmaceuticals in December 2015. "We are excited to have the support of three world-class pharmaceutical companies to expand our drug development efforts from ALS into new RNA binding proteins known to modulate Tau, one of the hallmark pathological proteins involved in Alzheimer's disease," said Glenn Larsen, Ph.D., Aquinnah's President and Chief Executive Officer.
PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
|Day's Range||33.71 - 33.96|
|52 Week Range||29.83 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||28.89|
|Dividend & Yield||1.28 (3.76%)|
|1y Target Est||N/A|